Nanjing Well Pharmaceutical Co Ltd

Nanjing Well Pharmaceutical Group Co., Ltd. is engaged in the research, development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to pharmaceutical companies in China and internationally. Its excipients serve injection, oral, and topical applications, and it also offers active pharmaceutical ingredients such as polidocanol and polyethylene glycol 3350/4000. The company provides a range of synthetic lubricating base oils, additives, and specialty chemicals, as well as products from its Yangzhou well and research institute, including various fatty acids and their esters. Formerly known as Nanjing Well Pharmaceutical Co., Ltd., it changed its name to Nanjing Well Pharmaceutical Group Co., Ltd. in April 2020 and was founded in 2000, based in Nanjing, China.

603351.CG3

Weier Pharmaceutical Releases 2026 Interim Report with Net Profit of 76.7829 Million Yuan

Weier Pharmaceutical released its 2026 interim report on August 22, 2026. The company's total operating revenue was 740 million yuan, net profit attributable to the parent company was 76.7829 million yuan, and net cash inflow from operating activities was 94.053 million yuan. The company's latest asset-liability ratio was 26.56%, gross margin was 27.61%, down 0.46 percentage points from the same period last year, latest ROE was 4.29%, and diluted earnings per share was 0.57 yuan. The company's latest total asset turnover was 0.29 times, inventory turnover was 2.55 times, number of shareholders was 5,464, and the top ten shareholders held 90.508 million shares, accounting for 66.83% of total share capital.

603351.CG

Jiemian·28dRead more →